Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Healthcare Biotechnology
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Noxopharm Ltd > Further update from Investor Relations
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by somguyincanadaon Jan 21, 2015 3:40pm
146 Views
Post# 23345357

RE:RE:RE:Further update from Investor Relations

RE:RE:RE:Further update from Investor RelationsI bought into NOX several years ago and the position I took was a long one.  I didn't buy into this company for a measly $1 share value.  I expect way more.  NOX is worth way more.

The current trend is encouraging, but we've seen it before.  I need something more substantial before I can truly get excited.  Someone wake me up if we (ever) break 50 cents.  Let's get together for some drinks if it (ever) reaches $1.  But let's really celebrate only if it pushes past $2 ... whcih I truly believe it has the potential of doing.

Good luck to the longs.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities